| 04110 |
Cell cycle |
13 |
7.76E−6 |
PCNA, CDKN2A, BUB1B, CDC7, TTK, SMC1B, CDC20, CCNB1, PTTG1, CDK1, MCM4, MCM5, MCM2 |
| 05200 |
Pathways in cancer |
29 |
2.77E−5 |
LAMA2, CKS1B, FGF7, EDNRA, EDNRB, RUNX1T1, PDGFRB, PDGFRA, JUP, CDKN2A, MMP1, ITGA2, PTCH1, FN1, IGF2, MITF, FOS, IGF1, WNT16, GNG11, ESR1, AR, CXCL12, GSTA4, CKS2, BIRC5, FGFR2, GSTM5, FGF10 |
| 04512 |
ECM-receptor interaction |
9 |
1.36E−4 |
TNXB, VWF, LAMA2, ITGA2, ITGA8, SPP1, FN1, HMMR, ITGA9 |
| 05412 |
Arrhythmogenic right ventricular cardiomyopathy (ARVC) |
8 |
2.93E−4 |
GJA1, LAMA2, JUP, ITGA2, ITGA8, DSG2, DSC2, ITGA9 |
| 05218 |
Melanoma |
8 |
2.93E−4 |
PDGFRB, PDGFRA, FGF7, CDKN2A, PDGFD, MITF, IGF1, FGF10 |
| 04151 |
PI3K-Akt signaling pathway |
20 |
3.18E−4 |
PDGFRB, PDGFRA, TNXB, VWF, LAMA2, ITGA2, IGF2, FN1, IGF1, GNG11, AREG, EREG, GYS2, FGF7, PDGFD, SPP1, ITGA8, FGFR2, FGF10, ITGA9 |
| 04510 |
Focal adhesion |
13 |
9.45E−4 |
PDGFRB, PDGFRA, TNXB, VWF, LAMA2, ITGA2, FN1, IGF1, MYLK, PDGFD, SPP1, ITGA8, ITGA9 |
| 04270 |
Vascular smooth muscle contraction |
10 |
0.001189 |
ACTA2, GUCY1A2, PPP1R14A, EDNRA, EDN3, MYH11, MRVI1, AVPR1A, ACTG2, MYLK |
| 03030 |
DNA replication |
5 |
0.001491 |
PCNA, RFC4, MCM4, MCM5, MCM2 |
| 04114 |
Oocyte meiosis |
9 |
0.002920 |
CDC20, AR, CCNB1, PTTG1, CDK1, PGR, IGF1, SMC1B,AURKA |
